What are the current American Thyroid Association (ATA) guidelines for the assessment and management of thyroid nodules and differentiated thyroid cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Latest ATA Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer

The most current American Thyroid Association guidelines for differentiated thyroid cancer were published in 2025, while the most recent comprehensive guidelines for thyroid nodules remain the 2015 version (revised 2016). 12

Key Updates in the 2025 ATA DTC Guidelines

The 2025 guidelines represent a major revision focusing specifically on the patient journey from initial cancer diagnosis through long-term management 1. These guidelines emphasize:

  • Initial staging and risk assessment following cancer diagnosis
  • Treatment response assessment as a critical driver of ongoing management decisions
  • Patient-reported outcomes integrated into care recommendations
  • Radioactive iodine-refractory disease management stratified into four decision groups: monitoring, directed therapies, systemic therapies, or clinical trial enrollment

The guidelines maintain editorial independence from the ATA and use a modified GRADE system for evidence appraisal 1.

Thyroid Nodule Assessment (2015/2016 ATA Guidelines)

Ultrasound Risk Stratification

The 2015 ATA guidelines introduced a pattern-based sonographic risk stratification system that fundamentally changed nodule management 32. This system classifies nodules into five categories:

High Suspicion Pattern (70-90% malignancy risk):

  • Solid hypoechoic nodule with one or more of: irregular margins, microcalcifications, taller-than-wide shape, rim calcifications with soft tissue extrusion, or evidence of extrathyroidal extension 2

Intermediate Suspicion Pattern (10-20% malignancy risk):

  • Hypoechoic solid nodule with smooth margins without microcalcifications, extrathyroidal extension, or taller-than-wide shape 2

Low Suspicion Pattern (5-10% malignancy risk):

  • Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric solid areas without microcalcifications, irregular margins, extrathyroidal extension, or taller-than-wide shape 2

Very Low Suspicion Pattern (<3% malignancy risk):

  • Spongiform or partially cystic nodules without any suspicious features 2

Benign Pattern (<1% malignancy risk):

  • Purely cystic nodules 2

FNA Biopsy Thresholds Based on Sonographic Pattern

The sonographic pattern directly determines FNA size thresholds 2:

  • High suspicion nodules: FNA at ≥1 cm
  • Intermediate suspicion nodules: FNA at ≥1 cm
  • Low suspicion nodules: FNA at ≥1.5 cm
  • Very low suspicion nodules: Consider FNA at ≥2 cm
  • Benign pattern: No FNA regardless of size

Nodules <1 cm should generally be observed rather than biopsied, even with suspicious features, unless there are concerning clinical risk factors (personal/family history of thyroid cancer, history of head/neck radiation, suspicious lymph nodes, or extrathyroidal extension) 2.

Important Caveat: Non-Classifiable Nodules

Approximately 7.8% of nodules cannot be classified using the ATA system 4. These non-classifiable nodules have a pooled malignancy risk of 20.3%, comparable to intermediate suspicion nodules, and should be managed accordingly 4.

Initial Thyroid Function Testing

Measure serum TSH as the initial laboratory test 2:

  • If TSH is low: Measure free T4 and free T3; consider radionuclide thyroid scan to assess for autonomously functioning nodules
  • If TSH is elevated: Measure thyroid peroxidase antibodies (TPOAb) and free T4
  • Do not routinely measure serum calcitonin unless medullary thyroid carcinoma is suspected based on FNA results or family history 52

Differentiated Thyroid Cancer Management Principles

Risk Stratification Drives Management

The 2015 ATA guidelines expanded the definition of "low risk" disease to include patients with small-volume lymph node involvement (≤5 lymph nodes, each <2 mm in central neck) 62. This change significantly impacts treatment intensity.

Three-tiered risk stratification 2:

Low Risk:

  • Intrathyroidal papillary thyroid cancer
  • No vascular invasion
  • Clinical N0 or ≤5 pathologic N1 micrometastases (<0.2 cm in largest dimension)
  • No distant metastases
  • Complete tumor resection
  • No aggressive histology

Intermediate Risk:

  • Microscopic extrathyroidal extension
  • Vascular invasion
  • Clinical N1 or >5 pathologic lymph node metastases (all <3 cm)
  • Multifocal papillary microcarcinoma with extrathyroidal extension and BRAF V600E mutation
  • Aggressive histology variants

High Risk:

  • Macroscopic extrathyroidal extension
  • Incomplete tumor resection
  • Distant metastases
  • Postoperative serum thyroglobulin suggestive of distant metastases
  • Pathologic N1 with any metastasis ≥3 cm

Response to Therapy Classification

A critical innovation in the 2015 guidelines is the four-category "response to therapy" system that guides long-term management and TSH suppression targets 32:

Excellent Response:

  • No clinical, biochemical, or structural evidence of disease
  • Suppressed thyroglobulin <0.2 ng/mL or TSH-stimulated thyroglobulin <1 ng/mL
  • TSH target: 0.5-2 mU/L (normal range)
  • Risk of recurrence: 1-4%

Biochemical Incomplete Response:

  • Abnormal thyroglobulin levels without structural disease
  • Suppressed thyroglobulin ≥1 ng/mL or stimulated thyroglobulin ≥10 ng/mL, or rising anti-thyroglobulin antibody levels
  • TSH target: 0.1-0.5 mU/L
  • Risk of recurrence: 20%

Structural Incomplete Response:

  • Persistent or newly identified structural disease
  • TSH target: <0.1 mU/L
  • Risk of recurrence: 50-85%

Indeterminate Response:

  • Nonspecific biochemical or structural findings that cannot be confidently classified
  • TSH target: 0.1-0.5 mU/L
  • Risk of recurrence: 15-20%

Surgical Management

For low-risk papillary thyroid carcinoma (unifocal, intrathyroidal, <4 cm, clinical N0), thyroid lobectomy is sufficient 27. This represents a major shift toward less aggressive surgery.

Total thyroidectomy is recommended for:

  • Tumors >4 cm
  • Gross extrathyroidal extension
  • Clinical evidence of lymph node metastases
  • Distant metastases
  • Bilateral thyroid disease
  • Personal history of radiation exposure
  • Familial thyroid cancer

Following the 2015 guidelines, lobectomy rates increased from 16% to 25%, though total thyroidectomy remains predominant 7.

Comparison with Other Guidelines

ACR TI-RADS vs ATA Guidelines

The ACR TI-RADS (2017) uses higher size thresholds for FNA compared to ATA guidelines 89:

  • TR5 (high suspicion): FNA at ≥1 cm
  • TR4 (moderately suspicious): FNA at ≥1.5 cm
  • TR3 (mildly suspicious): FNA at ≥2.5 cm
  • TR1-TR2: No FNA recommended

ACR TI-RADS demonstrates higher specificity (fewer unnecessary biopsies) compared to ATA guidelines, while maintaining comparable sensitivity 9. The ACR system successfully classifies all nodules, whereas 4.4-17.9% of nodules cannot be classified using ATA criteria 9.

AACE/ACE/AME Guidelines (2016)

The AACE guidelines use a three-tier ultrasound risk classification 555:

Class 3 (High Risk - 50-90% malignancy):

  • Marked hypoechogenicity
  • Spiculated/microlobulated margins
  • Microcalcifications
  • Taller-than-wide shape
  • Extrathyroidal growth or pathologic adenopathy
  • FNA at ≥10 mm

Class 2 (Intermediate Risk - 5-15% malignancy):

  • Slightly hypoechoic or isoechoic with ovoid-to-round shape
  • FNA at >20 mm

Class 1 (Low Risk - ~1% malignancy):

  • Mostly cystic (>50%) with reverberating artifacts
  • Isoechoic spongiform nodules
  • FNA only when >20 mm AND increasing in size or risk history present

Critical difference: AACE recommends monitoring nodules <5 mm regardless of appearance, and considers watchful waiting for 5-10 mm high-risk nodules based on clinical context 55.

Common Pitfalls to Avoid

  1. Do not biopsy functional ("hot") nodules on scintigraphy unless they have suspicious ultrasound features 52

  2. Do not perform routine calcitonin screening in all thyroid nodule patients—only when medullary thyroid carcinoma is suspected 55

  3. Do not use levothyroxine suppression therapy for benign nodules in euthyroid patients—it is ineffective and potentially harmful 55

  4. Do not biopsy more than 2 nodules in multinodular glands when selecting based on risk criteria 55

  5. For PET-detected thyroid incidentalomas with focal FDG uptake, always perform ultrasound evaluation and FNA due to high malignancy risk (approximately 35%) 55

  6. Do not assume all patients aged 45-54 years with thyroid cancer require aggressive treatment—the AJCC 8th edition changed the age cutoff to 55 years, reclassifying many patients to lower-stage disease 6

References

Research

2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.

Thyroid : official journal of the American Thyroid Association, 2025

Guideline

comparison of diagnostic performance between the american college of radiology thyroid imaging reporting and data system and american thyroid association guidelines: a systematic review.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.